Autologous hematopoietic stem cell transplantation for multiple sclerosis – if confused or hesitant,remember: ‘Treat with standard immune suppressive drugs and if no inflammation,no response’
Restricted accessEditorialFirst published online June, 2012
Autologous hematopoietic stem cell transplantation for multiple sclerosis – if confused or hesitant,remember: ‘Treat with standard immune suppressive drugs and if no inflammation,no response’
BurtRKBurnsWHessA. Bone marrow transplantation for multiple sclerosis. Bone Marrow Transplant1995; 16(1): 1–6.
2.
BurtRKAbinunMFarge-BancelD. Risks of immune system treatments. Science. 2010; 328(5980): 825–826.
3.
BurtRKLohYPearceW. Clinical applications of blood-derived and marrow-derived stem cells for nonmalignant diseases. JAMA2008; 299(8): 925–936.
4.
LoberizaFRJrZhangMJLeeSJ. Association of transplant center and physician factors on mortality after hematopoietic stem cell transplantation in the United States. Blood2005; 105(7): 2979–2987
5.
FargeDLabopinMTyndallA. Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years’ experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases. Haematologica2010; 95(2): 284–292.
6.
BurtRKCohenBARussellE. Hematopoietic stem cell transplantation for progressive multiple sclerosis: failure of a total body irradiation-based conditioning regimen to prevent disease progression in patients with high disability scores. Blood2003; 102(7): 2373–2378
7.
NashRABowenJDMcSweeneyPA. High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Blood2003 Oct; 102(7): 2364–2372.
8.
OpenshawHLundBTKashyapA. Peripheral blood stem cell transplantation in multiple sclerosis with busulfan and cyclophosphamide conditioning: report of toxicity and immunological monitoring. Biol Blood Marrow Transplant2000; 6(5A): 563–575.
9.
AtkinsHFreedmanM. Immune ablation followed by autologous hematopoietic stem cell transplantation for the treatment of poor prognosis multiple sclerosis. Methods Mol Biol2009; 549: 231–246.
10.
BurtRKMarmontAOyamaY. Randomized controlled trials of autologous hematopoietic stem cell transplantation for autoimmune diseases: the evolution from myeloablative to lymphoablative transplant regimens. Arthritis Rheum2006; 54(12): 3750–3760.
11.
SaccardiRFreedmanMSSormaniMP. on behalf of the European Blood and Marrow Transplantation Group, the Center for International Blood and Marrow Research, and the aHSCT in MS International Study Group. A prospective, randomized, controlled trial of autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: a position paper. Mult Scler2012, [Epub ahead of print]
BurtRKShahSJDillK. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet2011; 378(9790): 498–506.
14.
CouriCEOliveiraMCStracieriAB. C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA2009; 301(15): 1573–1579.
15.
VoltarelliJCCouriCEStracieriAB. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA2007; 297(14): 1568–1576.
16.
BurtRKLohYCohenB. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study. Lancet Neurol2009; 8(3): 244–253.
17.
HamerschlakNRodriguesMMoraesDA. Brazilian experience with two conditioning regimens in patients with multiple sclerosis: BEAM/horse ATG and CY/rabbit ATG. Bone Marrow Transplant2010; 45(2): 239–248.
18.
MarriottJJMiyasakiJMGronsethG. Evidence Report. The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology2010; 74(18): 1463–1470.
19.
CohenJABarkhofFComiG. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med2010; 362(5): 402–415
TanCSKoralnikIJ. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol2010; 9(4): 425–437
22.
O’DayKMeyerKMillerRM. Cost-effectiveness of natalizumab versus fingolimod for the treatment of relapsing multiple sclerosis. J Med Econ2011; 14(5): 617–627.
23.
MuraroPADouekDCPackerA. Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients. J Exp Med2005; 201(5): 805–816.
24.
TrappBDPetersonJRansohoffRM. Axonal transection in the lesions of multiple sclerosis. N Engl J Med1998; 338(5): 278–285.
BurtRKShahSJGheorghiadeM. Hematopoietic stem cell transplantation for systemic sclerosis: if you are confused, remember: “it is a matter of the heart”. J Rheumatol2012; 39(2): 206–209.
MancardiGLSormaniMPDi GioiaM. Autologous haematopotoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience. Mult Scler2012; [Epub ahead of print]
